Clinical Scorecard: Minimally Invasive Robotic Surgery via Transanal Approach for Rectal Tumors: A Comprehensive Review of Innovations and Outcomes
At a Glance
Category
Detail
Condition
Rectal neoplasms including T1-T2 adenocarcinomas and neuroendocrine tumors
Key Mechanisms
Robotic transanal minimally invasive surgery (TAMIS) platforms enabling sphincter-preserving local excision with enhanced visualization and instrument articulation
Target Population
Patients with benign and malignant rectal lesions suitable for local excision, including early-stage rectal cancers
Care Setting
Tertiary surgical centers with access to advanced robotic platforms
Key Highlights
Robotic TAMIS achieves high R0 resection rates (84–94%) with favorable local recurrence rates (~8.3%) for malignant rectal tumors.
Technological evolution from multiport to single-port robotic systems has improved operative efficiency, ergonomics, and reduced specimen fragmentation.
Robotic TAMIS demonstrates superiority over laparoscopic approaches with lower conversion rates (4% vs. 12%) and reduced 2-year local recurrence.
Guideline-Based Recommendations
Diagnosis
Utilize screening programs to detect early-stage rectal neoplasms amenable to local excision.
Perform thorough staging to identify tumor type and stage, focusing on T1-T2 adenocarcinomas and neuroendocrine tumors.
Management
Consider robotic TAMIS for organ-preserving local excision in selected patients with early-stage rectal tumors.
Select appropriate robotic platform generation based on tumor location and technical feasibility to optimize outcomes.
Use robotic TAMIS as a salvage excision option for residual or recurrent lesions post non-surgical management.
Monitoring & Follow-up
Implement median follow-up of at least 28 months to monitor local recurrence rates, especially in T2 tumors where recurrence risk is higher.
Conduct regular oncologic surveillance post-procedure to detect and manage recurrences early.
Risks
Recognize increased local recurrence risk (12–15%) in T2 adenocarcinomas requiring careful patient selection.
Account for technical challenges such as instrument collision and limited triangulation in early robotic platforms.
Consider economic implications and cost-effectiveness which remain incompletely characterized.
Patient & Prescribing Data
1,284 patients undergoing robotic TAMIS for benign and malignant rectal lesions across 26 studies
Robotic TAMIS yields high rates of negative margins and low conversion rates, with improved outcomes in T1 adenocarcinomas and neuroendocrine tumors; single-port systems reduce operative and docking times enhancing procedural efficiency.
Clinical Best Practices
Employ robotic TAMIS preferentially for T1 rectal adenocarcinomas and neuroendocrine tumors to maximize oncologic control.
Utilize advanced single-port robotic platforms to improve ergonomics and reduce operative time.
Ensure multidisciplinary evaluation for patient selection, balancing oncologic risk and functional preservation.
Maintain rigorous follow-up protocols to detect local recurrence, particularly in higher-risk T2 tumors.
Incorporate robotic TAMIS as part of organ-preserving strategies alongside watch-and-wait approaches.
